Company intelligence / Profile preview

Shanghai Jingshan Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Jingshan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on developing innovative antibody-based therapies for cancer and autoimmune disorders. The company utilizes its proprietary J-Body platform to engineer bispecific and multi-specific antibodies with optimized drug-like properties and enhanced therapeutic windows. Its lead program, JS001, is a bispecific antibody targeting both PD-L1 and CD47, currently undergoing clinical evaluation for advanced malignancies. Jingshan Bio aims to address unmet medical needs through its deep expertise in protein engineering and immunology.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

GCK-01

Unknown

Beyond the preview

Go deeper on Shanghai Jingshan Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Jingshan Biotechnology.

Explore the full profile